Latest News


Inpex Transfers 10% Stake in Masela Block Offshore Indonesia

Rigzone.com | 3 days 9 hours 49 minutes ago

Inpex announced that its affiliate, Inpex Masela, Ltd., has signed an agreement with PT EMP Energi Indonesia (EMPI), a subsidiary of PT Energi Mega Persada Tbk. (EMP), which is a leading Indonesian upstream oil and gas company, to transfer a 10% participating interest in the Masela Block in the Arafura Sea, Indonesia. The transaction is subject to the Indonesian Government approval and satisfaction of certain other conditions.... (more)


Covidien says FDA extends Exalgo review

Charlotte Observer (N.C.), The | 3 days 10 hours 14 minutes ago

NEW YORK Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo. ... (more)


Wire Business News

Sacramento Bee (Calif.), The | 3 days 10 hours 19 minutes ago

NEW YORK -- Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo.... (more)


Covidien says FDA extends review on pain drug Exalgo to Feb. 22

Star Tribune (Minneapolis-St. Paul, Minn.) | 3 days 10 hours 22 minutes ago

NEW YORK - Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo.... (more)


The Investment Column: Despite strengths, S&N is looking expensive

Independent (London), The | 3 days 10 hours 50 minutes ago

Smith & Nephew; Aquarius Platinum; Games Workshop... (more)


UPDATE 1-Covidien says FDA extends review of opiod pain drug

Reuters | 3 days 11 hours 45 minutes ago

Nov 20 (Reuters) - Covidien Plc (COV.N) said U.S. health regulators extended the review period of its experimental opioid pain drug by three months to Feb. 22, 2010.... (more)


Pinning Down Stock Prices Using Options

Wall Street Journal, The | 3 days 19 hours 43 minutes ago

NEW YORK?Shares of Intuitive Surgical have a better-than-average chance of closing Friday's session near $280, according to a recent analysis of the company's options.... (more)




 1  2  3  

41 Stories  |   RSS Feed



Sign up for AdvaMed SmartBrief



Designed specifically for manufacturers of medical devices, health care information systems and diagnostic products, AdvaMed SmartBrief is a FREE e-mail newsletter. By providing a summary of the day's most important medical technologies news, AdvaMed SmartBrief saves you time and keeps you smart. Learn more

Latest Blog Postsview more


Job Listingsview more


Companies in the news